Top Tweets for #CLONEVO
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
Enjoyed my conversation with @zklaassen_md @urotoday to discuss #CLONEVO, our window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive #bladdercancer @WCMGUcancer @WeillCornell
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
#CLONEVO study: Targeting cyclin D1 amplifications in #BladderCancer with abemaciclib. @FaltasLab @WeillCornell joins @zklaassen_md @GACancerCenter to discuss this window-of-opportunity trial evaluating abemaciclib, a CDK4/6 inhibitor, in cisplatin-ineligible muscle-invasive bladder cancer #MIBC. #WatchNow > https://t.co/HT6TcDNo0Q
🔎 @FaltasLab gives an overview of the #CLONEVO study, which is the first window-of-opportunity trial of a CDK4/6 inhibitor—abemaciclib—in muscle-invasive #bladdercancer: https://t.co/fWgX5xJ8Yb
🗣️Bladder Rapid Oral Abstracts #ASCO25
👉Abs4520: Dr @FaltasLab presenting #abemaciclib cis-ineligible MIBC on #CLONEVO
🩺Clinical implications:
- Preoperative #abemaciclib in MIBC demonstrated promising efficacy and tolerability while modulating cell cycle-dependent pathways
- Consider future studies in combination with ADCs (EV/P)
-------------------------------------------------------
n = 20 (16/20 males)
5/20 cT4.
3 didn't undergo RC, 1 withdrew consent.
💉abema (200mg BID PO) x 4-8 weeks prior to RC
✅ pCR = 18.8% (3/16)
✅ downstaging = 31.3% (5/16)
⚠️G3 TRAE anemia (4/20), abdominal pain (1/20) and diarrhea (1/20)
🩻 Imaging Mass Cytometry of pre/post 👇 RB1 phosphorylation
🧬 VAF 👇after abema by 20.5% (p = 0.04)
🧬 ctDNA tumor fraction(TF)👇after abema by 28.6%
⭐️Pt w/ CCND1 amplification most significant decrease in TF (63.8%) highlighting CCND1 as a potential response biomarker
👥@DrRosenbergMSK @MichvdHeijden @FaltasLab @SuzanneColeMD @cnsternberg @MattGalsky @bergsa83 @alantanmd @tompowles1 @DrKarieRuncie @BraunMDPhD @PGrivasMDPhD @shilpaonc @AmandaNizamMD @DrKarineTawagi @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @ReginaBarCar @crisbergerot @kidneycan @KidneyCancer @ASCO @OncoAlert @OncBrothers @OncLive @BladderCancerUS
Excited to see these outstanding presentations advancing care for patients with genitourinary malignancies! Thank you @OncoAlert for highlighting our #CLONEVO investigator-initiated trial https://t.co/opOXhj0Z5Y See you tomorrow! 🏢 at the Arie Crown Theater at 2.15 PM 🕐 #ASCO25 @ASCO
The #ASCO25 #OncoAlertTOP10 Abstracts in #GUOncology These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸
#ProstateCancer #BladderCancer #kidneyCancer
⭐Abs 4518 SURE-02: NEOADJUVANT SACITUZUMAB GOVITECAN PLUS PEMBROLIZUMAB, FOLLOWED BY RESPONSE-ADAPTED BLADDER SPARING AND ADJUVANT PEMBRO, IN MUSCLE-INVASIVE BLADDER CANCER
⭐Abs 4521 AREN1721: AXITINIB+NIVOLUMAB COMBINATION THERAPY VS. SINGLE AGENT NIVOLUMAB FOR THE TREATMENT OF TFE/TRANSLOCATION RENAL CELL CARCINOMA ACROSS ALL AGE GROUPS
⭐Abs 5000 CAN-2409+PRODRUG IN COMBINATION WITH STANDARD OF CARE EXTERNAL BEAM RADIATION (EBRT) FOR NEWLY DIAGNOSED LOCALIZED PROSTATE CANCER
⭐Abs LBA5006 SUNRISE-4: TAR-200 + CETRELIMAB OR CET ALONE AS NEOADJUVANT THERAPY IN MUSCLE-INVASIVE BLADDER CANCER INELIGIBLE FOR OR REFUSE NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY
⭐Abs 5019 TALAPRO-2: HOMOLOGOUS RECOMBINATION REPAIR ALTERATIONS BY GENE SUBGROUP AND POTENTIAL ASSOCIATIONS WITH EFFICACY IN THE HRR-DEFICIENT POPULATION
⭐Abs 4500 CHECKMATE 901 PHASE 3 TRIAL: IPI/NIVO VS GEM/CARBO AS 1L THERAPY IN CISPLATIN-INELIGIBLE
PATIENTS WITH MUC
⭐Abs 4514 FIVE-YEAR FOLLOW-UP KEYNOTE-564 STUDY OF ADJUVANT PEMBROLIZUMAB (PEMBRO)
FOR THE TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA
⭐Abs 4516 PDIGREE (ALLIANCE A031704): IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC)
⭐Abs 4517
CREST: SASANLIMAB IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN (BCG) IN BCG-NAIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): EVENT-FREE SURVIVAL (EFS)
⭐Abs 4506 COMBINATION CASDATIFAN PLUS CABOZANTINIB EXPANSION COHORT OF PHASE 1 ARC-20
STUDY IN PREVIOUSLY TREATED PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
⭐Abs LBA4513 ENLIGHTED INTERIM RESULTS OF EFFICACY AND SAFETY OF PADELIPORFIN VASCULAR TARGETED PHOTODYNAMIC THERAPY IN TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER
⭐Abs 4520 CLONEVO: PREOPERATIVE ABEMACICLIB FOR CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER (MIBC) WITH MOLECULAR RESPONSE ASSESSMENT
⭐Abs LBA5012 AN OPEN LABEL RANDOMIZED NON-INFERIORITY TRIAL COMPARING ADJUVANT PLATINUM PLUS PACLITAXEL TO PLATINUM PLUS 5-FU AFTER CURATIVE RESECTION IN HIGH-RISK PENILE CARCINOMA
Lead @nataliagandur @ReginaBarCar @yekeduz_emre @weoncologists
Faculty: @apolo_andrea @DrChoueiri @PGrivasMDPhD @ravikanesvaran @neerajaiims @amerseburger @drenriquegrande @Silke_Gillessen
Ping GU Faculty
@montypal @crisbergerot @DrDanielHeng @DrChoueiri @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1
@EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas
@DrYukselUrun
#OncoAlertAF
@acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
#ASCO25 #CLONEVO Preoperative Abemaciclib for Cisplatin Ineligible #MIBC with Molecular Response Assessment - Results from CLONEVO — the first trial of pre-op abemaciclib in cisplatin-ineligible MIBC. The CDK4/6 inhibitor showed promising pathologic responses and on-target molecular effects, including E2F pathway suppression and tumor burden reduction via ctDNA. A potential path forward for biomarker-driven therapy. #BladderCancer #UroOnc #PrecisionMedicine > https://t.co/8YO1uML1AG @FaltasLab @zklaassen_md @EliLillyandCo @DrScottTagawa @cnsternberg @DrJonesNauseef @ASCO
Beyond excited to present the results of our investigator-initiated #CLONEVO trial at #ASCO25 @ASCO! 🏢Arie Crown Theater on May 31, 2025 🕐
Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in:
✅ 31% pathologic downstaging
✅ Clear on-target activity through ⬇️ Rb phosphorylation & Ki67. Measured by spatial immune mass cytometry in more than 630,000 single cells from matched pre-/post-abemaciclib tissues 🔬
🩸🧪 Serial ctDNA analysis shows tumor fraction reduction was driven by abema, not TURBT
☑️Tumors with CCND1 ⭕️ amplification are more likely to respond (very cool underlying biology!)
⬇️ decreased expression of critical DNA damage proteins TOBP1 and RAD51. Providing rationale for testing sequencing CDK4/6 inhibitors after DNA-damaging therapies, including ADCs, to inhibit cancer cells from repairing double-strand DNA breaks
https://t.co/omrwyHhKJd
@MHosmanMD @cnsternberg @DoctorMargolis @DrJonesNauseef @DrAnaMolina @DrDavidNanus @rohitjainMD @scientistatlrge @DrMhidalgo @notSoJunkDNA @willbfx @ElementoLab @SuzanneColeMD @DrScottTagawa #clinicaltrials #teamscience
4.#CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment. Abema resulted in pathologic complete response in 18.8% (3/16) and downstaging in 31.3% (5/16).
Stellar neoadjuvant/adjuvant clinical trials session today #AACR25 @AACR chaired by @aparna1024! @FaltasLab presented #CLONEVO trial, neoadjuvant abemaciclib for cis-ineligible #bladdercancer - we participated @utswcancer led by @SuzanneColeMD!
Progress in #BladderCancer research. @FaltasLab @EngIPM joins @CaPsurvivorship @NUFeinbergMed to discuss the cutting edge aspects of his research on #urothelial #cancer and the #CLONEVO trial. #WatchNow on UroToday > https://t.co/9f57l3JOOV @WeillCornell
Progress in #BladderCancer research. @FaltasLab @EngIPM joins @CaPsurvivorship @NUFeinbergMed to discuss the cutting edge aspects of his research on #urothelial #cancer and the #CLONEVO trial. #WatchNow on UroToday > https://t.co/9f57l3sdql @WeillCornell
Last Seen Hashtags on Sotwe
secretstory
Seen from France
incestomaefilho
Seen from Brazil
omegle
Seen from United States
blackededit
Seen from United States
1win
Seen from Argentina
xlii or #TEENAGER or #momson or #nolimit() +filter:native_video
Seen from Turkey
audrisummers
Seen from United States
pasutrilpg
Seen from Indonesia
KAW
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
82.9M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers